566 related articles for article (PubMed ID: 16784976)
21. Histopathologic analysis of atypical lesions in image-guided core breast biopsies.
Bonnett M; Wallis T; Rossmann M; Pernick NL; Bouwman D; Carolin KA; Visscher D
Mod Pathol; 2003 Feb; 16(2):154-60. PubMed ID: 12591968
[TBL] [Abstract][Full Text] [Related]
22. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
23. Stages on the way to breast cancer.
Going JJ
J Pathol; 2003 Jan; 199(1):1-3. PubMed ID: 12474219
[TBL] [Abstract][Full Text] [Related]
24. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
Carder PJ; Garvican J; Haigh I; Liston JC
Histopathology; 2005 Mar; 46(3):320-7. PubMed ID: 15720418
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical staining for cyclin D1 and Ki-67 aids in the stratification of atypical ductal hyperplasia diagnosed on breast core biopsy.
Hameed O; Ghali VS; Tartter PI; Mizrachi H
Am J Clin Pathol; 2005 Dec; 124(6):862-72. PubMed ID: 16416735
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
MacGrogan G
Ann Pathol; 2009 Jun; 29(3):188-93. PubMed ID: 19619824
[No Abstract] [Full Text] [Related]
28. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
29. Loss of myoepithelium is variable in solid papillary carcinoma of the breast.
Nicolas MM; Wu Y; Middleton LP; Gilcrease MZ
Histopathology; 2007 Nov; 51(5):657-65. PubMed ID: 17927587
[TBL] [Abstract][Full Text] [Related]
30. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
31. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
Pinder SE; Ellis IO
Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
[TBL] [Abstract][Full Text] [Related]
32. Papillary lesions of the breast: selected diagnostic and management issues.
Collins LC; Schnitt SJ
Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
[TBL] [Abstract][Full Text] [Related]
33. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay.
Yu Q; Niu Y; Yu Y; Ding X; Shi Y
Breast Cancer Res Treat; 2009 Apr; 114(3):433-40. PubMed ID: 18425676
[TBL] [Abstract][Full Text] [Related]
35. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
36. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma.
Tajima S; Maeda I; Kanemaki Y; Nakajima Y; Tatsunami S; Fukuda M; Takagi M
Pathol Int; 2010 Jun; 60(6):459-65. PubMed ID: 20518901
[TBL] [Abstract][Full Text] [Related]
38. Breast pathology practice: most common problems in a consultation service.
Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO
Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ of the breast.
Masood S; Sim SJ; Lu L
Cancer Detect Prev; 1992; 16(4):225-35. PubMed ID: 1281040
[TBL] [Abstract][Full Text] [Related]
40. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
